AI Quick Summary

We’re thrilled to celebrate the latest achievements of our Switzerland Innovation Park Basel Area - Main Campus resident Alentis Therapeutics!💊 Alentis Therapeutics has received FDA clearance for an Investigational New Drug application targeting squamous cancers1, a big step in their oncology pipeline. We can’t wait to see the impact of their upcoming clinical trials. Well done, Roberto Iacone, Chief Executive Officer of Alentis , & team!👉Learn more about how you can start your own success story at the Main Campus: https://maincampus.ch/

Post Metadata

• Author: Switzerland Innovation Digital
• Published Date: 10/22/2024 1:05:59 PM
• Modified Date: 10/22/2024 1:05:59 PM

Post Description

We’re thrilled to celebrate the latest achievements of our Switzerland Innovation Park Basel Area - Main Campus resident Alentis Therapeutics!

💊 Alentis Therapeutics has received FDA clearance for an Investigational New Drug application targeting squamous cancers1, a big step in their oncology pipeline. We can’t wait to see the impact of their upcoming clinical trials. Well done, Roberto Iacone, Chief Executive Officer of Alentis , & team!

👉Learn more about how you can start your own success story at the Main Campus: https://maincampus.ch/